These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 38754400)
1. A Multicentre, Randomized Trial in Adults with de novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia to Assess the Efficacy of Ponatinib versus Imatinib in Combination with Low-Intensity Chemotherapy, to Compare End of Therapy with Indication for Stem Cell Transplantation versus Tyrosine Kinase Inhibitor, Blinatumomab, and Chemotherapy in Optimal Responders, and to Evaluate Blinatumomab in Suboptimal Responders (GMALL-EVOLVE). Lang F; Pfeifer H; Brüggemann M; Hermann E; Serve H; Goekbuget N Oncol Res Treat; 2024; 47(9):430-433. PubMed ID: 38754400 [TBL] [Abstract][Full Text] [Related]
2. Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents? Sohn SK; Lee JM; Jang Y; Lee Y; Na J; Cho HJ; Moon JH; Baek DW Expert Rev Hematol; 2024 Jul; 17(7):353-359. PubMed ID: 38755522 [TBL] [Abstract][Full Text] [Related]
3. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. Jabbour E; Kantarjian HM; Aldoss I; Montesinos P; Leonard JT; Gómez-Almaguer D; Baer MR; Gambacorti-Passerini C; McCloskey J; Minami Y; Papayannidis C; Rocha V; Rousselot P; Vachhani P; Wang ES; Wang B; Hennessy M; Vorog A; Patel N; Yeh T; Ribera JM JAMA; 2024 Jun; 331(21):1814-1823. PubMed ID: 38722621 [TBL] [Abstract][Full Text] [Related]
4. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports. Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010 [TBL] [Abstract][Full Text] [Related]
5. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. Jabbour E; Haddad FG; Short NJ; Kantarjian H JAMA Oncol; 2022 Sep; 8(9):1340-1348. PubMed ID: 35834222 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute. Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977 [TBL] [Abstract][Full Text] [Related]
7. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Jabbour E; Short NJ; Ravandi F; Huang X; Daver N; DiNardo CD; Konopleva M; Pemmaraju N; Wierda W; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Khoury JD; Jorgensen J; Jain N; Alvarez J; O'Brien S; Kantarjian H Lancet Haematol; 2018 Dec; 5(12):e618-e627. PubMed ID: 30501869 [TBL] [Abstract][Full Text] [Related]
8. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623 [TBL] [Abstract][Full Text] [Related]
9. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Ribera JM; García-Calduch O; Ribera J; Montesinos P; Cano-Ferri I; Martínez P; Esteve J; Esteban D; García-Fortes M; Alonso N; González-Campos J; Bermúdez A; Torrent A; Genescà E; Mercadal S; Martínez-Lopez J; García-Sanz R Blood Adv; 2022 Sep; 6(18):5395-5402. PubMed ID: 35675590 [TBL] [Abstract][Full Text] [Related]
10. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339 [TBL] [Abstract][Full Text] [Related]
11. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Jabbour E; Short NJ; Jain N; Huang X; Montalban-Bravo G; Banerjee P; Rezvani K; Jiang X; Kim KH; Kanagal-Shamanna R; Khoury JD; Patel K; Kadia TM; Daver N; Chien K; Alvarado Y; Garcia-Manero G; Issa GC; Haddad FG; Kwari M; Thankachan J; Delumpa R; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H Lancet Haematol; 2023 Jan; 10(1):e24-e34. PubMed ID: 36402146 [TBL] [Abstract][Full Text] [Related]
12. A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens. Xiong ZY; Shen YJ; Zhang SZ; Zhu HH Hematology; 2024 Dec; 29(1):2335856. PubMed ID: 38581291 [TBL] [Abstract][Full Text] [Related]
13. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480 [TBL] [Abstract][Full Text] [Related]
14. The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia. Wu X; Lu S; Zhang X; Yang Z; Sun A; Wu D; Zhou H; Miao M Cancer Med; 2024 Sep; 13(17):e70161. PubMed ID: 39240182 [TBL] [Abstract][Full Text] [Related]
15. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Othman T; Koller P; Tsai NC; Yang D; Pourhassan H; Agrawal V; Ngo D; Chen J; Farol L; Spielberger R; Sahebi F; Al Malki MM; Cai JL; Sandhu KS; Mansour J; Salhotra A; Ali H; Aribi A; Arslan S; Marcucci G; Forman SJ; Stein AS; Nakamura R; Pullarkat V; Aldoss I; Mei M Am J Hematol; 2024 Sep; 99(9):1680-1690. PubMed ID: 38804599 [TBL] [Abstract][Full Text] [Related]
16. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046 [TBL] [Abstract][Full Text] [Related]
17. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926 [TBL] [Abstract][Full Text] [Related]
18. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study. Leotta S; Markovic U; Pirosa MC; Stella S; Tringali S; Martino M; Specchia G; Carluccio P; Risitano AM; Grimaldi F; Vigna E; Palmieri F; Palmieri R; Annunziata M; Pisapia G; Palazzo G; Milone GA; Pelle AC; Scalise L; Di Giorgio MA; Bulla A; Leotta V; Di Raimondo F; Milone G Ann Hematol; 2021 Jul; 100(7):1743-1753. PubMed ID: 33774681 [TBL] [Abstract][Full Text] [Related]
19. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090 [TBL] [Abstract][Full Text] [Related]
20. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Abou Dalle I; Jabbour E; Short NJ; Ravandi F Curr Treat Options Oncol; 2019 Jan; 20(1):4. PubMed ID: 30675645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]